A Phase 3 interventional study of QAB149 and Placebo in Chronic Obstructive Pulmonary Disease: COPD, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Switzerland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-02-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 48th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 26th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 74th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study purpose is to evaluate the effect of QAB149
This is a multicenter, randomized, double-blinded, single-dose, cross-over, placebo-controlled study. The primary endpoint was chosen to demonstrate the superiority of a single-dose of the combined inhalation vs. the mono inhalation regarding the Inspiratory Capacity (IC) peak value. A total of 78 patients will be randomized to complete two visits with two single doses of treatment. Patients will be randomized in a cross-over manner. Treatment visits will be separated by a study medication wash-out period.Treatments will be administered in a blinded fashion.
The patients will be male and female patients, ≥40 years of age, with a documented diagnosis of moderate or severe COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and >10-pack years history of smoking, FEV1 \<80% and ≥30% of the predicted normal value.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
Drug: QAB149 · Drug: Placebo
Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
Drug: QAB149 · Drug: NVA237
Inspiratory Capacity (IC) Peak Value
IC was measured with spirometry conducted according to internationally accepted standards. Peak IC was defined as the maximum IC of the mean at one of the post-dose measurements (30min, 60min, 120min, 180min and 240min).
Time frame: Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours
Forced Expiratory Volume in One Second (FEV1)
FEV1 was measured with spirometry conducted according to internationally accepted standards. FEV1 was at 30, 60, 120, 180, and 240 minutes post-dose. Spirometry equipment and performance of spirometric testing had to be in accordance with standards as outlined in the American Thoracic Society for the Standardization of Spirometry recommendations. The spirometry equipment used during the study had to meet or exceed these minimal ATS recommendations
Time frame: Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours
Inspiratory Capacity (IC)
During the 4 hours following inhalation of the study treatment, inspiratory capacity (IC) was measured with spirometry conducted according to internationally accepted standards. IC was measured at 30, 60, 120, 180, and 240 minutes post-dose
Time frame: within 4h after dosing
Forced Volume Capacity (FVC)
FVC was measured with spirometry conducted according to internationally accepted standards. Measurements were made 30, 60, 120, 180, and 240 minutes post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time
Time frame: Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours
Total Lung Capacity (TLC)
TLC was measured with spirometry conducted according to internationally accepted standards. Peak TLC was calculated as the mean of the three Functional Residual Capacity peak measurements plus the mean of the three Inspiratory Capacity measurements which were measured each at 30, 60, 120, 180 and 240 minutes post dose
Time frame: Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours
Airway Resistance (Raw)
Raw was measured with spirometry conducted according to internationally accepted standards. Raw was the mean of the measurements which were measured each at 30, 60, 120, 180 and 240 minutes
Time frame: Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours
| Milestone | Sequence A | Sequence B |
|---|---|---|
| Started | 39 | 39 |
| Safety population | 39 | 38 |
| Full analysis population (fas) | 38 | 38 |
| Completed | 36 | 36 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Medical or ethical, noncompliance | 2 | 0 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Patient request | 0 | 1 |
| Milestone | Sequence A | Sequence B |
|---|---|---|
| Started | 36 | 36 |
| Completed | 35 | 36 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
IC was measured with spirometry conducted according to internationally accepted standards. Peak IC was defined as the maximum IC of the mean at one of the post-dose measurements (30min, 60min, 120min, 180min and 240min).
| Liters | Sequence A | Sequence B |
|---|---|---|
| Day 0 (n=38, 38) | 2.87 ± 0.808 | 2.94 ± 0.777 |
| Day 6 (n=36, 36) | 2.99 ± 0.856 | 2.85 ± 0.707 |
FEV1 was measured with spirometry conducted according to internationally accepted standards. FEV1 was at 30, 60, 120, 180, and 240 minutes post-dose. Spirometry equipment and performance of spirometric testing had to be in accordance with standards as outlined in the American Thoracic Society for the Standardization of Spirometry recommendations. The spirometry equipment used during the study had to meet or exceed these minimal ATS recommendations
| Liters | Sequence A | Sequence B |
|---|---|---|
| Day (0) 30 min post-dose | 1.49 ± 0.442 | 1.57 ± 0.505 |
| Day (0) 1 hour post-dose | 1.50 ± 0.440 | 1.60 ± 0.506 |
| Day (0) 2 hour post-dose | 1.51 ± 0.437 | 1.60 ± 0.506 |
| Day (0) 3 hour post-dose | 1.53 ± 0.430 | 1.59 ± 0.500 |
| Day (0) 4 hour post-dose | 1.53 ± 0.434 | 1.60 ± 0.492 |
| Day (6) 30 min post-dose | 1.59 ± 0.437 | 1.52 ± 0.473 |
| Day (6) 1 hour post-dose | 1.63 ± 0.465 | 1.53 ± 0.463 |
| Day (6) 2 hour post-dose | 1.66 ± 0.462 | 1.55 ± 0.476 |
| Day (6) 3 hour post-dose | 1.65 ± 0.455 | 1.56 ± 0.470 |
| Day (6) 4 hour post-dose | 1.64 ± 0.473 | 1.56 ± 0.459 |
During the 4 hours following inhalation of the study treatment, inspiratory capacity (IC) was measured with spirometry conducted according to internationally accepted standards. IC was measured at 30, 60, 120, 180, and 240 minutes post-dose
| Liters | Sequence A | Sequence B |
|---|---|---|
| Day (0) 30 min post-dose | 2.67 ± 0.771 | 2.75 ± 0.751 |
| Day (0) 1 hour post-dose | 2.67 ± 0.799 | 2.79 ± 0.774 |
| Day (0) 2 hour post-dose | 2.69 ± 0.803 | 2.71 ± 0.709 |
| Day (0) 3 hour post-dose | 2.74 ± 0.811 | 2.69 ± 0.800 |
| Day (0) 4 hour post-dose | 2.74 ± 0.823 | 2.74 ± 0.754 |
| Day (6) 30 min post-dose | 2.79 ± 0.826 | 2.40 ± 0.724 |
| Day (6) 1 hour post-dose | 2.80 ± 0.810 | 2.72 ± 0.759 |
| Day (6) 2 hour post-dose | 2.86 ± 0.846 | 2.74 ± 0.689 |
| Day (6) 3 hour post-dose | 2.83 ± 0.841 | 2.69 ± 0.719 |
| Day (6) 4 hour post-dose | 2.85 ± 0.799 | 2.68 ± 0.699 |
FVC was measured with spirometry conducted according to internationally accepted standards. Measurements were made 30, 60, 120, 180, and 240 minutes post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time
| Liters | Sequence A | Sequence B |
|---|---|---|
| Day (0) 30 min post-dose | 2.98 ± 0.917 | 3.00 ± 0.839 |
| Day (0) 1 hour post-dose | 3.00 ± 0.966 | 3.02 ± 0.846 |
| Day (0) 2 hour post-dose | 3.01 ± 0.947 | 3.04 ± 0.862 |
| Day (0) 3 hour post-dose | 3.08 ± 0.946 | 3.04 ± 0.872 |
| Day (0) 4 hour post-dose | 3.07 ± 0.968 | 3.07 ± 0.852 |
| Day (6) 30 min post-dose | 3.19 ± 1.002 | 2.96 ± 0.788 |
| Day (6) 1 hour post-dose | 3.25 ± 1.047 | 2.97 ± 0.807 |
| Day (6) 2 hour post-dose | 3.29 ± 1.018 | 2.99 ± 0.754 |
| Day (6) 3 hour post-dose | 3.32 ± 1.003 | 2.98 ± 0.794 |
| Day (6) 4 hour post-dose | 3.30 ± 1.012 | 2.96 ± 0.797 |
TLC was measured with spirometry conducted according to internationally accepted standards. Peak TLC was calculated as the mean of the three Functional Residual Capacity peak measurements plus the mean of the three Inspiratory Capacity measurements which were measured each at 30, 60, 120, 180 and 240 minutes post dose
| Liters | Sequence A | Sequence B |
|---|---|---|
| Day (0) 30 min post-dose | 7.20 ± 1.587 | 6.81 ± 1.144 |
| Day (0) 1 hour post-dose | 7.17 ± 1.559 | 6.79 ± 1.197 |
| Day (0) 2 hour post-dose | 7.06 ± 1.658 | 6.81 ± 1.190 |
| Day (0) 3 hour post-dose | 7.14 ± 1.662 | 6.82 ± 1.198 |
| Day (0) 4 hour post-dose | 7.21 ± 1.608 | 6.78 ± 1.247 |
| Day (6) 30 min post-dose | 7.20 ± 1.664 | 6.79 ± 1.243 |
| Day (6) 1 hour post-dose | 7.12 ± 1.576 | 6.80 ± 1.312 |
| Day (6) 2 hour post-dose | 7.21 ± 1.641 | 6.80 ± 1.213 |
| Day (6) 3 hour post-dose | 7.23 ± 1.561 | 6.81 ± 1.304 |
| Day (6) 4 hour post-dose | 7.30 ± 1.691 | 6.93 ± 1.376 |
Raw was measured with spirometry conducted according to internationally accepted standards. Raw was the mean of the measurements which were measured each at 30, 60, 120, 180 and 240 minutes
| cmH2O/l/s | Sequence A | Sequence B |
|---|---|---|
| Day (0) 30 min post-dose | 5.13 ± 2.243 | 4.74 ± 1.810 |
| Day (0) 1 hour post-dose | 5.19 ± 2.561 | 4.61 ± 1.881 |
| Day (0) 2 hour post-dose | 5.21 ± 2.496 | 4.43 ± 1.849 |
| Day (0) 3 hour post-dose | 5.07 ± 2.528 | 4.53 ± 1.748 |
| Day (0) 4 hour post-dose | 5.18 ± 2.535 | 4.48 ± 1.866 |
| Day (6) 30 min post-dose | 4.73 ± 2.540 | 5.18 ± 2.130 |
| Day (6) 1 hour post-dose | 4.47 ± 2.323 | 4.97 ± 1.861 |
| Day (6) 2 hour post-dose | 4.31 ± 2.119 | 4.71 ± 1.822 |
| Day (6) 3 hour post-dose | 4.30 ± 2.161 | 4.77 ± 1.989 |
| Day (6) 4 hour post-dose | 4.30 ± 2.170 | 4.78 ± 1.939 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sequence A | — | 0/39 (0%) | 5/39 (12.8%) |
| Sequence B | — | 0/38 (0%) | 3/38 (7.9%) |
| Event | Sequence A | Sequence B |
|---|---|---|
| Forced expiratory volume decreasedInvestigations | 1/39 | 1/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/39 | 1/38 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/39 | 1/38 |
| NasopharyngitisInfections and infestations | 1/39 | 0/38 |
| Inspiratory capacity decreasedInvestigations | 1/39 | 0/38 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/39 | 0/38 |
Demographic summary by treatment group (safety population, N = 77)
| Age, Continuous(Years) | Sequence A | Sequence B | Total |
|---|---|---|---|
| Mean | 65.62 ± 9.247 | 64.18 ± 7.447 | 64.91 ± 8.383 |
| Sex: Female, Male(Participants) | Sequence A | Sequence B | Total |
|---|---|---|---|
| Female | 14 | 17 | 31 |
| Male | 25 | 21 | 46 |
The record gives a start of Nov 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →